Amgen stock after-hours at EUR 357.43: minus 0.33 percent versus the Lang & Schwarz prior close
Published on 10/05/2026 at 18:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock was at EUR 357.43 in after-hours trading at 6:08 p.m. CEST on October 5, 2026, down 0.33 percent versus the Lang & Schwarz prior close of EUR 358.63. The quote was reported by Lang & Schwarz.
After-hours trading
The Lang & Schwarz price was EUR 1.20 below the prior close. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Amgen stock.
Dazodalibep Phase 3 results
In a September 22, 2026 release, Amgen said its Phase 3 OASIZ 301 study of dazodalibep met its primary endpoint in adults with Sjögren’s disease and moderate-to-severe systemic disease activity. The company reported statistically significant and clinically meaningful improvement at Week 48, measured by the EULAR Sjögren’s Syndrome Disease Activity Index, with improvements observed as early as Week 4 and sustained through Week 48.
Amgen said OASIZ 301 was a randomized, double-blind, placebo-controlled study with approximately 621 participants. The company plans to present detailed data at an upcoming medical meeting and said its Phase 3 OASIZ 303 study is expected to complete in the fourth quarter of 2026.
